Thymosin alpha-1 (Tα-1) 10 mg

Thymosin alpha-1 (Tα-1) is a synthetic peptide derived from the natural thymosin fraction found in bovine thymus glands. This product is intended solely for academic, scientific, and laboratory research applications where controlled experimentation is conducted in accordance with established protocols. Tα-1 has been extensively studied in vitro and in animal models for its potential immunomodulatory, antiviral, and anticancer properties. Due to its biological activity, Tα-1 is a regulated compound under many jurisdictions and must be handled with strict adherence to laboratory safety and regulatory guidelines.

Research Context

Thymosin alpha-1 was first isolated in the 1960s from calf thymus glands and subsequently synthesized in the 1980s. The peptide comprises 14 amino acids and shares structural homology with other thymosin family members, though it exhibits distinct biological functions. Early research emphasized its role in modulating cell-mediated immunity by enhancing the activity of natural killer (NK) cells—a critical component of the innate immune response. Subsequent studies expanded its characterization into areas beyond immunity, including potential antiviral effects, tumor cell suppression, and modulation of inflammation.

Research Overview

Tα-1 has been evaluated in a wide range of in vitro and in vivo studies, primarily within animal models and cell cultures. Its mechanisms of action remain multifaceted, though the primary focus has historically been on enhancing NK cell function. This peptide is often used to investigate immune responses, viral susceptibility, tumor metastasis, and regenerative processes. While human clinical data are not applicable to this product due to its classification as a research reagent, peer-reviewed studies provide foundational insights into its biochemical and pharmacological properties.

Key Research Focus Areas

• Immunomodulation: Tα-1 has been studied for its capacity to enhance NK cell activity, which may influence responses to infections, vaccines, and immune-compromised conditions in experimental settings.
• Antiviral Activity: Research indicates that Tα-1 may interfere with viral replication in certain cell types, including those infected with herpesviruses, influenza, and HIV. This property has been explored in pre-clinical contexts, though human applications are beyond the scope of this product.
• Antitumor Effects: Studies in animal models have demonstrated that Tα-1 may suppress tumor growth and metastasis by modulating immune surveillance mechanisms, including the recruitment of cytotoxic lymphocytes.
• Inflammatory Response Regulation: Investigations suggest Tα-1 may mitigate excessive inflammation in certain pathological states, including autoimmune responses and ischemic injury.
• Regenerative Biology: Emerging research explores Tα-1’s potential role in tissue repair, particularly in contexts where immune responses must be finely tuned to support regenerative processes without inducing chronic inflammation.

Safety and Compliance

Due to its biological activity, Tα-1 is a controlled substance under many national and international regulations. This product must be handled only in licensed research facilities under the supervision of qualified personnel. Users are responsible for ensuring compliance with all applicable laws, including those governing the possession, storage, and distribution of bioactive compounds. Misuse or unauthorized human/animal exposure can result in severe health risks and legal consequences.

For research use only. Not for human or animal consumption.